| Literature DB >> 28658614 |
S Julia Wu1, Yashar S Niknafs2, Stephanie H Kim1, Katherine Oravecz-Wilson3, Cynthia Zajac3, Tomomi Toubai3, Yaping Sun3, Jayendra Prasad3, Daniel Peltier4, Hideaki Fujiwara3, Israel Hedig3, Nathan D Mathewson5, Rami Khoriaty3, David Ginsburg6, Pavan Reddy7.
Abstract
Cross-presentation initiates immune responses against tumors and viral infections by presenting extracellular antigen on MHC I to activate CD8+ T cell-mediated cytotoxicity. In vitro studies in dendritic cells (DCs) established SNARE protein SEC22B as a specific regulator of cross-presentation. However, the in vivo contribution of SEC22B to cross-presentation has not been tested. To address this, we generated DC-specific Sec22b knockout (CD11c-Cre Sec22bfl/fl) mice. Contrary to the paradigm, SEC22B-deficient DCs efficiently cross-present both in vivo and in vitro. Although in vitro small hairpin RNA (shRNA)-mediated Sec22b silencing in bone-marrow-derived dendritic cells (BMDCs) reduced cross-presentation, treatment of SEC22B-deficient BMDCs with the same shRNA produced a similar defect, suggesting the Sec22b shRNA modulates cross-presentation through off-target effects. RNA sequencing of Sec22b shRNA-treated SEC22B-deficient BMDCs demonstrated several changes in the transcriptome. Our data demonstrate that contrary to the accepted model, SEC22B is not necessary for cross-presentation, cautioning against extrapolating phenotypes from knockdown studies alone.Entities:
Keywords: RNA-seq; SEC22B; SNARE protein; cross-presentation; dendritic cell; off-target effect
Mesh:
Substances:
Year: 2017 PMID: 28658614 PMCID: PMC5539946 DOI: 10.1016/j.celrep.2017.06.013
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423